China Pharma Holdings Inc. Company Profile
NYSE: CPHIHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
China Pharma at a glance
China Pharma Holdings Inc. (NYSE: CPHI) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Haikou, China. China Pharma is led by Ms. Zhilin Li and employs about 215 people. At a market capitalization of $18.9 million, it is considered a small-cap company.
Its SEC Central Index Key (CIK) is 0001106644, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does China Pharma do?
China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection for edema diseases, hypertension, acute renal failure, hyperkalemia, hypercalcemia, and acute drug poisoning; and Candesartan for hypertension. It offers Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and Pseudophedrine Hydrochlorida sustained release tablets, as well as Hepatocyte growth-promoting factors, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. In addition, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection for nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It supplies its products to hospitals and OTC pharmacies through provincial and municipal pharmaceutical logistics companies. The company is based in Haikou, the People's Republic of China.
Business description based on the company's public filings.
Company information
- Legal name
- China Pharma Holdings Inc.
- Ticker
- NYSE: CPHI
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Ms. Zhilin Li
- Employees
- 215
- Headquarters
- No. 17, Jinpan Road, Haikou, China
- Phone
- 86 89 8668 11730
- Website
- chinapharmaholdings.com
- Market cap
- $18.86M
- SEC CIK
- 0001106644
- Latest annual report
- 10-K · Apr 1, 2026
Companies similar to China Pharma
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| COCPCocrystal Pharma Inc. | 0.95 | -2.05% | $18.30M | vs CPHI |
| MRKRMarker Therapeutics Inc. | 1.09 | -17.42% | $18.17M | vs CPHI |
| IGCIGC Pharma Inc. | 0.168 | -8.70% | $19.60M | vs CPHI |
| TXMDTherapeuticsMD Inc. | 1.71 | -5.52% | $19.79M | vs CPHI |
| ACETAdicet Bio Inc. | 2.14 | -13.01% | $20.03M | vs CPHI |
| RNAZTransCode Therapeutics Inc. | 1.16 | -10.77% | $20.07M | vs CPHI |
| KTTAPasithea Therapeutics Corp. | 0.4787 | -0.48% | $17.59M | vs CPHI |
| AARDAardvark Therapeutics Inc. | 0.9226 | -7.74% | $20.20M | vs CPHI |